Semaglutide Injection
Type 2 Diabetes, Obesity
Key Facts
About Lupin
Lupin is a mission-driven global pharmaceutical company focused on improving access to essential and advanced medicines through the development and commercialization of generic drugs, complex formulations, and biosimilars. Founded in 1968, it has grown into a top-tier generics player with a significant presence in the US, India, and other key markets, underpinned by robust R&D and manufacturing capabilities. Its strategy centers on expanding its complex generics and specialty portfolio, advancing its biosimilars pipeline, and leveraging operational excellence to drive sustainable, long-term growth.
View full company profileTherapeutic Areas
Other Type 2 Diabetes, Obesity Drugs
| Drug | Company | Phase |
|---|---|---|
| Generic Semaglutide (Oral) | Dr. Reddy's Laboratories | Development |
| GLP-1 Agonist Program | Biolingus | Pre-clinical |
| GLP-1 Receptor Agonist (Gan & Lee) | Lupin Limited | Clinical Development |
| Semaglutide (Oral Generic) | Dr. Reddy's Laboratories | Pre-launch |